

Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

NCT07486206

Status	RECRUITING
Phase	Not Applicable
Sponsor	Hospital de Granollers
Enrollment	152 participants

Key Eligibility Criteria

Inclusion (6)

- Age e 18 years.
- Established diagnosis of interstitial lung disease (ILD).
- Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.
- Under active follow-up at the participating ILD center.
- Able to attend the required follow-up procedures included in the study visit.

... and 1 more (see full listing online)

Exclusion (5)

- Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).
- Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute heart failure, or other acute conditions).
- Participation in another interventional clinical trial that may alter visit frequency or follow-up structure.
- Cognitive impairment preventing informed consent or completion of questionnaires.
- Patient refusal to participate or refusal to allow data collection.

Locations (1 total)

Hospital General de Granollers, Granollers, Barcelona, Spain